Pharvaris, a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases like hereditary angioedema (HAE), has updated the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) ...
Abviax's Obefazimod shows promising phase 2b results in ulcerative colitis, with superior safety and efficacy compared to existing treatments, supporting a buy rating. The drug's novel mechanism ...
Pegozafermin is ETNB’s long-acting FGF21 analog. It’s undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB ...
Vera Therapeutics, Inc. announced that its ORIGIN Phase 3 trial for atacicept, a treatment for immunoglobulin A nephropathy (IgAN), achieved its primary endpoint by demonstrating a significant ...
SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, ...
Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the result fell short of the bar set by existing drugs, the German drugmaker is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results